Gyre Therapeutics, Inc. Share Price
GYREGyre Therapeutics, Inc. Stock Performance
Open $7.95 | Prev. Close $7.49 | Circuit Range N/A |
Day Range $7.67 - $7.95 | Year Range $6.11 - $12.42 | Volume 4,543 |
Average Traded $7.81 |
Gyre Therapeutics, Inc. Share Price Chart
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Mar-26 | $7.36 | $7.50 | -1.57% |
13-Mar-26 | $7.76 | $7.62 | -2.31% |
12-Mar-26 | $8.21 | $7.80 | -6.19% |
11-Mar-26 | $8.32 | $8.31 | +2.02% |
10-Mar-26 | $8.35 | $8.15 | -0.37% |
09-Mar-26 | $7.79 | $8.18 | +5.55% |
06-Mar-26 | $8.10 | $7.75 | -0.77% |
FAQs on Gyre Therapeutics, Inc. Share Price
Can I buy Gyre Therapeutics, Inc. shares in India?
What is the share price of Gyre Therapeutics, Inc.?
What is the 5 year returns of Gyre Therapeutics, Inc.?
What are the high & low stock price of Gyre Therapeutics, Inc. today?
What is the 52-week high and low of Gyre Therapeutics, Inc. stock?